The RV144 clinical trial of a prime/boost immunizing regimen using recombinant canary pox and two gp120 proteins was previously shown to have a 31.2% efficacy rate.
http://www.citeulike.org/user/ammurira/article/12303468
http://www.citeulike.org/user/ammurira/article/12303468
